Intelligence / Healthtech / New Clinical Trials / Hexin (Suzhou) Pharmaceutical Technology Co., Ltd
Hexin (Suzhou) Pharmaceutical Technology Co., Ltd
6 Nov 2026: Trial registered · Evaluation of the I-phase Clinical Trial of 177Lu-HX02 Injection in Patients With Advanced Malignant Solid Tumors. Recorded in the ClinicalTrials.gov (US National Library of Medicine).
- Posted
- 6 Nov 2026
- Title
- Evaluation of the I-phase Clinical Trial of 177Lu-HX02 Injection in Patients With Advanced Malignant Solid Tumors
- Conditions
- Soft Tissue Sarcoma, Non-small Cell Lung Cancer
- Phase
- Phase 1
- Study Type
- Interventional
- Status
- Enrolling By Invitation
- Countries
- China
- Country
- China
- Reference
- NCT07920822
- Location
- China
A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.
- United States leads with 192 of 777, then China (171).
- 777 added in the 30 days to 18 Nov 2026.
Find the decision makers at Hexin (Suzhou) Pharmaceutical Technology Co., Ltd
AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.
Across AOS Research
Other records for Hexin (Suzhou) Pharmaceutical Technology Co., Ltd in our registers.
More from China
New Clinical Trials
Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.